
Abogen
Founded Year
2019Stage
Series C - II | AliveTotal Raised
$1.134BValuation
$0000Last Raised
$300M | 3 yrs agoAbout Abogen
Abogen operates as a plant-based pharmaceutical research company. It focuses on the research and development of messenger ribonucleic acid (mRNA) drugs to create antidotes against human disease. The company was founded in 2019 and is based in Suzhou, China.
Loading...
Loading...
Expert Collections containing Abogen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Abogen is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,249 items
Abogen Patents
Abogen has filed 21 patents.
The 3 most popular patent topics include:
- food additives
- hepatotoxins
- polysaccharides

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/24/2016 | 3/7/2023 | Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors | Grant |
Application Date | 10/24/2016 |
---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors |
Status | Grant |
Latest Abogen News
Sep 26, 2024
The mRNA Vaccine and Therapeutics Market is valued at USD 9 billion in 2024 growing at a CAGR of 16% during the forecast period from 2026 to 2035. Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that plays a crucial role in transferring genetic information necessary for protein synthesis. The instructions encoded in mRNA for producing proteins are relayed from a DNA strand to ribosomes, where they are translated into functional proteins. The advent of mRNA therapeutics and vaccines has emerged as a groundbreaking alternative to traditional treatment methods. Following the COVID-19 pandemic, mRNA therapeutics and vaccines have gained substantial attention, establishing themselves as a revolutionary class of drugs for treating not only COVID-19 but also various other conditions, including infectious diseases, cancer, genetic disorders, and more. To date, four mRNA-based vaccines have received approval for COVID-19 treatment, with numerous additional candidates currently undergoing evaluation as potential therapies. The overall success of mRNA-based vaccines and therapies against COVID-19 has piqued the interest of many investors, particularly in small and emerging biotechnology companies focused on mRNA technology. The achievements in mRNA therapeutics and vaccines have spurred increased research activity in the next-generation RNA therapeutics market. A robust pipeline of mRNA-based therapeutics and vaccines is also propelling growth in the mRNA synthesis and manufacturing sector, as drug developers seek contract services to scale up the production of mRNA-based treatments. Research Coverage: A general introduction to mRNA, featuring insights on the historical evolution of mRNA therapeutics and vaccines. It also presents elaborate description on advantages associated with mRNA therapeutics and vaccines. It also features some of the key applications of both mRNA therapeutics and mRNA vaccines. Additionally, the chapter includes details on the various types of delivery routes and delivery strategies for mRNA drugs. Further, the chapter discusses the challenges associated with large scale adoption of mRNA therapeutics and vaccines and the associated future perspectives. A detailed overview of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development, type of drug candidate, therapeutic area, type of delivery system, type of molecule encoded and route of administration. A detailed overview of the current market of players engaged in the development of mRNA vaccine and therapeutics. An in-depth company competitiveness analysis of players in mRNA vaccine and therapeutics domain, based on their developer strengthand number of therapeutic areas targeted. Elaborate profiles of key companies engaged in mRNA vaccine and therapeutics market. Each profile features a brief overview of the company, financial information, mRNA vaccines and therapeutics pipeline, recent developments and an informed future outlook. A review of the various mRNA-focused initiatives undertaken by big pharma players, featuring a heat map representation that highlights mRNA therapeutics and vaccines under development, along with information on funding amount raised, partnership activity, and diversity of product portfolio, as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters. An analysis of start-ups in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development. This chapter also provides details on amount raised, number of investors and number of deals inked. An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, therapeutic area, study design, type of sponsor / collaborator, leading industry players,enrolled patient population and geography. An analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players and regional distribution of partnership activity that have been undertaken in this domain, since 2013. A detailed analysis of various investments made by players in this domain, since 2013, based on several relevant parameters, such as year of funding, type of funding, amount invested, therapeutic area, most active players and key investors. An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent, publication year, geographical region, CPC symbols, leading industry playersand patent valuation. An in-depth analysis of the factors that can impact the growth of the market. It also features information on key drivers, potential restraints, emerging opportunities, and existing challenges within the mRNA vaccine and therapeutics market. A detailed mRNA vaccine and therapeutics market forecast analysis with our estimates of the existing market size, market value and future opportunity for mRNA vaccine and therapeutics companies over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035. Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different application area, such as COVID-19 and other indications. Detailed projections of the current and future opportunity within the mRNA vaccines & therapeutics market across different target disease indication, such as influenza, respiratory syncytial virus infection and cytomegalovirus diseases. Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different geographical regions. Leading Market Companies 18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA 18.1. Chapter Overview 18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035 19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION 19.1. Chapter Overview 19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035 20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS 20.1. Chapter Overview 20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035 For more information about this report visit https://www.researchandmarkets.com/r/5o5abx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment
Abogen Frequently Asked Questions (FAQ)
When was Abogen founded?
Abogen was founded in 2019.
Where is Abogen's headquarters?
Abogen's headquarters is located at Unit 501, Building B1, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou.
What is Abogen's latest funding round?
Abogen's latest funding round is Series C - II.
How much did Abogen raise?
Abogen raised a total of $1.134B.
Who are the investors of Abogen?
Investors of Abogen include 5Y Capital, New Frontier, DNE Capital, SoftBank, Mirae Asset Financial Group and 37 more.
Who are Abogen's competitors?
Competitors of Abogen include NeoCura.
Loading...
Compare Abogen to Competitors
NeoCura is committed to building a Ribonucleic acid (RNA) drug platform. It has built a multi-omics big data collection platform and multi-bionics database to perform in-depth drug target mining and fully automated drug design based on Artificial intelligence (AI) algorithms and core bioinformatic technologies. Through application in clinical innovative RNA drug development and next-generation and safe clinical precision diagnosis and treatment, it provides patients with one-stop full-cycle solutions from screening, diagnosis, and treatment to efficacy monitoring. It was founded in 2017 and is based in Beijing, China.
Loading...